Multicenter, open-label trial of PXD 101 in patients with relapsed/refractory peripheral T-cell lymphoma.

Zain, Jasmine; O'Connor, O.; Zinzani, P. L.; Norman, A.; Brown, Peter de Nully

doi:10.1200/jco.2010.28.15_suppl.e18565

Cited by 9 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Belinostat, a potent class I and II HDAC inhibitor, is being studied in a phase II clinical trial (ClinicalTrials.gov Identifier: NCT00865969) for patients with PTCL whose disease progressed after at least one line of systemic therapy. At a dose of 1000 mg/m 2 IV for days 1–5 of a 21-day cycle, the interim efficacy report for this trial has revealed an ORR of 32% with a median duration of response of 8 months (Zain et al, 2010). Panobinostat is a pan-HDAC inhibitor, tested across a spectrum of hematological malignancies, with few PTCL patients receiving this drug, although some responses have been reported in this patient population (Ottmann et al, 2008).…”

Section: Treatment For Relapsed/refractory Diseasementioning

confidence: 85%

Peripheral T-Cell Lymphomas: A Review of Current Approaches and Hopes for the Future

Skarbnik¹,

Burki²,

Pro³

2013

Front. Oncol.

View full text Add to dashboard Cite

show abstract

Section: Treatment For Relapsed/refractory Diseasementioning

confidence: 85%

Peripheral T-Cell Lymphomas: A Review of Current Approaches and Hopes for the Future

Skarbnik¹,

Burki²,

Pro³

2013

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Like romidepsin, belinostat has produced responses in patients diagnosed with PTCL 29 . Preliminary results from a phase II trial in lymphoma have been promising 30 .…”

Section: Histone Deacetylase Inhibitorsmentioning

confidence: 99%

Histone Deacetylase Inhibitors: Emerging Mechanisms of Resistance

et al. 2011

View full text Add to dashboard Cite

The histone deacetylase inhibitors (HDIs) have shown promise in the treatment of a number of hematologic malignancies, leading to the approval of vorinostat and romidepsin for the treatment of cutaneous T-cell lymphoma and romidepsin for the treatment of peripheral T-cell lymphoma by the U. S. Food and Drug Administration. Despite these promising results, clinical trials with the HDIs in solid tumors have not met with success. Examining mechanisms of resistance to HDIs may lead to strategies that increase their therapeutic potential in solid tumors. However, relatively few examples of drug-selected cell lines exist, and mechanisms of resistance have not been studied in depth. Very few clinical translational studies have evaluated resistance mechanisms. In the current review, we summarize many of the purported mechanisms of action of the HDIs in clinical trials and examine some of the emerging resistance mechanisms.

show abstract

“…Auf Basis von Phase II Studien sind in den USA, nicht jedoch in Europa die HDAC-Inhibitoren Romidepsin [56,57] und Belinostat [58], sowie der Inhibitor der Thymidilatsynthese Pralat rexat [59] beim rezidivierten/refraktären PTCL zugelassen. Für ALK+ ALCL zeigte die Anwen dung von des ALK-Tyrosinkinase-Inhibitors Crizotinib Wirksamkeit im Rezidiv [60,61].…”

Section: Rezidivtherapieunclassified